EZH2 and B-cell chronic lymphocytic leukemia: These results reflect the main findings of the published study, where it was shown that IGF1R is non-canonically activated in U-CLL through the EZH2-mediated recruitment of MYC in its promoter, resulting in further activation of the PI3K pathway (Kosalai et al., 2019).